Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to SBF2 is a long non-coding RNA gene transcribed from the opposite strand of the SBF2 locus. As an antisense lncRNA, its transcript overlaps the SBF2 gene and may regulate SBF2 expression or processing via transcriptional interference, chromatin modification, or RNA duplex formation. No protein product has been identified. Its specific biological function, disease associations, and clinical relevance remain uncharacterized. There is no documented direct role for this specific antisense transcript in cancer, inflammation, neurodegenerative disease, or other pathologies; however, antisense lncRNAs in general can participate in disease mechanisms through gene regulation. This target is a non-coding RNA, not a protein; it is an uncharacterized antisense transcript that may regulate the nearby SBF2 gene but is not recognized as a direct therapeutic target, biomarker, or established disease gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to SBF2 (ENSG00000305052).